New Horizons in Breast Cancer Treatment with the MUC-1 Vaccine

This experimental vaccine study targeting the MUC-1 protein on the surface of cancer cells stands out as the most successful breast cancer vaccine study conducted to date . It showed that combining the MUC-1 vaccine tecemotide with standard neoadjuvant systemic therapy significantly improved distant recurrence-free survival and overall survival in patients with breast cancer . These results provide the first concrete evidence demonstrating the potential and effectiveness of vaccines in breast cancer treatment, establishing a promising foundation for future research.

This study involving patients with early-stage breast cancer was presented at the ASCO 2024 Congress.

Important Terms Mentioned in the Article and Their Definitions:

• MUC-1: MUC-1 is a protein overexpressed in various cancers. Vaccines developed against it encourage the immune system to attack cancer cells.
• Tecemotide: A peptide vaccine developed against MUC-1.
• Neoadjuvant Treatment: Treatment given before surgery.
• Distant Recurrence-Free Survival: The length of time a patient survives without cancer spreading to another site.
• Pathologic Complete Response: A situation in which all cancer cells have disappeared after treatment.
• Residual Cancer Burden (RCB): The amount of cancer cells remaining after treatment.

The ABCSG 34 Trial

In the prospective, multicenter, two-arm phase 2 ABCSG 34 trial, Dr. Singer, head of gynecology at the Medical University of Vienna, and his team randomized 400 patients with HER2-negative early breast cancer to receive standard preoperative neoadjuvant treatment alone or with tecemotide , a MUC-1–targeted cancer vaccine.

• Related topic: Immunotherapy and Types of Cancer Vaccines

Study Design

Postmenopausal breast cancer patients with luminal A tumors received 6 months of letrozole as standard treatment. Postmenopausal patients for whom chemotherapy was the standard treatment, including those with triple-negative breast cancer or luminal B tumors, and all premenopausal participants received four cycles of epirubicin, cyclophosphamide, and docetaxel every 3 weeks.

The study's primary endpoint was residual cancer burden at surgery.

Long-term outcomes were analyzed in terms of distant recurrence-free survival and overall survival. Long-term outcome data were available for 291 women, of whom 236 received chemotherapy as standard treatment.

Results

• 7-Year Follow-Up Results:

  • 81% of patients who received tecemotide plus standard treatment were still alive at 7 years and metastasis-free .
  • In patients receiving standard treatment alone, metastasis-free overall survival at 7 years was 65%.
  • Adding tecemotide to standard treatment reduced the risk of distant recurrence by 47% [hazard ratio (HR): 0.53 (95% CI, 0.34-0.83; P = 0.005)].

• Overall Survival Rates:

  • Patients receiving tecemotide + standard treatment: 83%
  • Standard treatment alone: 68% (HR for overall survival, 0.53; 95% CI, 0.33-0.85; P = 0.008).

• Residual Cancer Burden at Surgery:

  • No significant increase in residual cancer burden at surgery was observed in patients receiving tecemotide plus standard neoadjuvant treatment compared with those receiving standard treatment alone.
    • Residual cancer burden in the tecemotide arm: 36.4%
    • Standard treatment alone: 31.5%
    • Tecemotide plus standard treatment in the chemotherapy group: 40.5%
    • Treatment alone in the chemotherapy group: 34.8%
    • These differences were not statistically significant (P = 0.42 and P = 0.37).

Commentary

The absence of a significant difference in residual cancer burden at surgery shows that pathologic complete response and residual cancer burden are not sufficient endpoints for cancer vaccine trials, and that we need to find new predictive/prognostic markers . More detailed exploratory studies are needed in this area.

In conclusion, tecemotide plus chemotherapy produced notable distant recurrence-free survival and overall survival results. Distant recurrence-free survival was 81% in the tecemotide plus chemotherapy group and 65% in the standard treatment group. Overall survival was recorded as 84% in the tecemotide group and 68% in the standard treatment group.

The researchers would like to see clinical trials investigating whether tecemotide can further improve responses in lung, breast, and potentially other MUC-1–expressing cancers. These studies aim to test tecemotide's effectiveness across a broader range of cancers.

Future phase 3 MUC-1 cancer vaccine trials will probably use mRNA technology . This points to a new stage in the development of cancer vaccines. We also need to understand why the vaccine sometimes works and sometimes does not. Research in this area has the potential to increase vaccine effectiveness and benefit a broader group of patients.